Biomedical subjects

Hans-Jürgen Gutke

Publications and source records attributed to Hans-Jürgen Gutke.

2 recordsLinked to original sources

PubMed2005

CC-10004 .

CC-10004, a phosphodiesterase 4 inhibitor and selective cytokine inhibitor, is under development by Celgene for the potential treatment of asthma, chronic obstructive pulmonary disease, inflammation and psoriasis. By October 2004, phase II trials in psoriasis had commenced.

3',5'-Cyclic-AMP Phosphodiesterases↗

PubMed2005

AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).

elbion (formerly ASTA Medica) and GlaxoSmithKline are developing an inhaled formulation of AWD-12-281 for the potential treatment of chronic obstructive pulmonary disease (COPD). By May 2005, phase II trials of this 5-hydroxyindole PDE4 inhibitor for COPD were ongoing.

3',5'-Cyclic-AMP Phosphodiesterases↗